FRLN | tickerfilter.com

Fundamental analysis

76%

Profitability 93%

Dept financing 25%

Liquidity 0%

Performance 90%

Performance

5 Days

0 0%

1 Month

0 0%

3 Months

0 0%

6 Months

0 0%

1 Year

0 0%

2 Year

0 0%

Key data

Stock price

$6.48

P/E Ratio

0.00

DAY RANGE

$6.48 - $6.48

EPS

$0.00

52 WEEK RANGE

$0.00 - $0.00

52 WEEK CHANGE

$0.00

MARKET CAP

0.000

YIELD

N/A

SHARES OUTSTANDING

2.432 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

N/A

BETA

0.00

PUBLIC FLOAT

AVERAGE 10 VOLUME

AVERAGE 30 VOLUME

Company detail

CEO:
Region: US
Website: https://www.freeline.life/
Employees: 0
IPO year: -

Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Biological Product (except Diagnostic) Manufacturing
Sector: Manufacturing

freeline is a biopharmaceutical company focused on the development and commercialisation of gene therapies for bleeding and other debilitating disorders based on a next-generation aav gene therapy platform developed by amit nathwani, professor of haematology at ucl and cso of freeline therapeutics http://www.freelinetx.com

FRLN - Freeline Therapeutics Holdings plc - ADR